Ambrisentan improves health and exercise capacity of PAH patients, find researchers
December 21, 2015
Ambrisentan is an orally active, once-daily medication currently approved for the treatment of PAH patients in the U.S. and other countries on the basis of two 12-week randomized, double-blind, placebo-controlled, multicenter efficacy trials. In these studies, the drug improved exercise capacity, along with other clinical indications of PAH disease severity, including clinical worsening.
Prior to their study, the researchers said most long-term PAH studies have focused primarily on exercise capacity and safety for up to one year, with very little description of clinical effectiveness of ambrisentan treatment.
The researchers in the current two-year study found that the two higher doses of the medication, 5 milligrams and 10 milligrams, provided a sustained benefit. The lower dosage used in the study, 2.5 milligrams, was less effective, the researchers said.
Source: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)